Altamira Therapeutics Stock Current Ratio
| CYTO Stock | USD 0.44 0.03 7.32% |
Altamira Therapeutics fundamentals help investors to digest information that contributes to Altamira Therapeutics' financial success or failures. It also enables traders to predict the movement of Altamira Stock. The fundamental analysis module provides a way to measure Altamira Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Altamira Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 1.38 | 1.31 |
Altamira | Current Ratio |
Altamira Therapeutics Company Current Ratio Analysis
Altamira Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Altamira Therapeutics Current Ratio | 0.77 X |
Most of Altamira Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Altamira Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Altamira Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Altamira Therapeutics is extremely important. It helps to project a fair market value of Altamira Stock properly, considering its historical fundamentals such as Current Ratio. Since Altamira Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Altamira Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Altamira Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Altamira Current Ratio Historical Pattern
Today, most investors in Altamira Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Altamira Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Altamira Therapeutics current ratio as a starting point in their analysis.
Altamira Therapeutics Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Altamira Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Altamira Therapeutics has a Current Ratio of 0.77 times. This is 73.54% lower than that of the Biotechnology sector and 89.0% lower than that of the Health Care industry. The current ratio for all United States stocks is 64.35% higher than that of the company.
Altamira Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Altamira Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Altamira Therapeutics could also be used in its relative valuation, which is a method of valuing Altamira Therapeutics by comparing valuation metrics of similar companies.Altamira Therapeutics is currently under evaluation in current ratio category among its peers.
Altamira Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Altamira Therapeutics from analyzing Altamira Therapeutics' financial statements. These drivers represent accounts that assess Altamira Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Altamira Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 9.1M | 14.0M | 21.9M | 4.1M | 1.4M | 1.4M | |
| Enterprise Value | 7.7M | 3.2M | 21.5M | 10.4M | 918.8K | 872.9K |
Altamira Fundamentals
| Return On Equity | -3.69 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 2.02 M | ||||
| Shares Outstanding | 3.78 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 3.13 % | ||||
| Number Of Shares Shorted | 31.09 K | ||||
| Price To Book | 0.26 X | ||||
| Price To Sales | 0.64 X | ||||
| Gross Profit | (2.18 M) | ||||
| EBITDA | (1.35 M) | ||||
| Net Income | (3.87 M) | ||||
| Cash And Equivalents | 984.19 K | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 99.66 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 0.77 X | ||||
| Book Value Per Share | 2.37 X | ||||
| Cash Flow From Operations | (11.51 M) | ||||
| Short Ratio | 0.60 X | ||||
| Earnings Per Share | 1.82 X | ||||
| Target Price | 4.5 | ||||
| Number Of Employees | 10 | ||||
| Beta | 2.44 | ||||
| Market Capitalization | 1.65 M | ||||
| Total Asset | 7.69 M | ||||
| Retained Earnings | (18.05 M) | ||||
| Working Capital | 334.24 K | ||||
| Net Asset | 7.69 M |
About Altamira Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Altamira Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altamira Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altamira Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Altamira Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altamira Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altamira Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Altamira Stock
| 0.7 | ME | 23Andme Holding | PairCorr |
| 0.92 | VALN | Valneva SE ADR Downward Rally | PairCorr |
| 0.71 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Altamira Stock
| 0.66 | KZR | Kezar Life Sciences | PairCorr |
| 0.59 | MLYS | Mineralys Therapeutics, Downward Rally | PairCorr |
| 0.34 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Altamira Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altamira Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altamira Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altamira Therapeutics to buy it.
The correlation of Altamira Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altamira Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altamira Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altamira Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Altamira Therapeutics Piotroski F Score and Altamira Therapeutics Altman Z Score analysis. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.82 | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.64) | Return On Assets (0.57) | Return On Equity (3.69) |
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.